Ask about KPV

Get a grounded answer across clinical evidence, community patterns, and risks.

Ask AI →

KPV

Also known as: Lysine-Proline-Valine

Healing Research Compound

Tripeptide (alpha-MSH C-terminal fragment)

Mechanism of Action

C-terminal fragment of alpha-MSH with anti-inflammatory activity; studied for gut inflammation and tissue repair without the pigmentation effects of full alpha-MSH.

1,089
Community Posts
319
Users Discussing
9
Research Articles
0

Reported Outcomes

Clinical grade reflects published research; Community grade reflects user reports (n=1,089).

Skin Health

Improvements in skin quality, firmness, and appearance

Clinical: D
Community: B
43% (317)
Inflammation

Reduction in inflammation and swelling

Clinical: A
Community: B
31% (180)
Joint Health

Joint pain relief and mobility improvements

Clinical: D
Community: B
28% (209)
Sleep Quality

Effects on sleep quality

Clinical: C
Community: B
25% (122)
Injury Recovery

Accelerated recovery from injuries and surgery

Clinical: B
Community: B
25% (123)
Energy Levels

Changes in energy and fatigue levels

Clinical: D
Community: B
12% (44)
Wound Healing

Wound healing and scar improvement

Clinical: C
Community: B
11% (50)
Mental/Mood

Effects on mood and cognitive function

Clinical: D
Community: B
10% (40)
Anti-Aging

Anti-aging and regenerative effects

Clinical: D
Community: B
9% (37)
Gut Healing

Gut lining repair and digestive health

Clinical: B
Community: B
8% (32)
Tendon & Ligament

Tendon and ligament repair and health

Clinical: D
Community: B
5% (23)
Hair Growth

Effects on hair growth and quality

Clinical: D
Community: B
4% (14)
Muscle Repair

Muscle recovery and repair from exercise or injury

Clinical: D
Community: A
2% (7)

Who Discusses KPV

From community reports with demographic data.

Gender

Male 53%
Female 47%

n=53

Age Distribution (limited data)

46
median age
range: 27-73
<30
30s
40s
50s
60+

n=29

Side Effects

Limited data

Based on 8 user reports (n=8). Frequency indicates how often each was mentioned.

Uncommon (1-5%)

Sting At Injection Site (From Klow Stack)
Mild 1 reports 10.0%
Swelling
Mild 1 reports 10.0%
Copper Uglies (Associated With Ghk-Cu
Mild 1 reports 10.0%
Klow)
Mild 1 reports 10.0%
Adrenaline-Type Rush Feeling
Mild 1 reports 10.0%
Hair Color Change (Roots Turning Mousey Brown)
Mild 1 reports 10.0%
Nausea
Mild 1 reports 10.0%

Risks & Warnings

Important safety considerations based on clinical data and community reports.

i

Injection Pain/Stinging

152 mentions

Users report less sting with more dilution and slower injection; light massage can help.

i

Injection Site Reactions

90 mentions

Local reactions are common and usually mild. Rotate injection sites.

Dosing

Standard Protocol

Starting Dose
200-500mcg daily (community protocols)
Titration
No established protocol
Half-life
Short (minutes)
Administration
Subcutaneous, oral, or topical (community use varies)

Community Dosing Patterns

Based on 73 mentions

Community-reported patterns, not medical advice.

500mcg daily
11
daily
7
1mg daily
3
300mcg daily
2
400mcg daily
2

Research

9
Total Articles
0
2
Reviews

Key Studies

The Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentials. Review

Cells (2023)

Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review. Review

Int J Med Sci (2025)

A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment. Preclinical

Bioact Mater (2024)

PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combined treatment of acute and chronic DSS-induced ColitiS. Preclinical

Front Pharmacol (2024)

Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers. Preclinical

Sci Adv (2026)

Commonly Stacked With

From community members' documented stacks involving KPV.

GHK-Cu 96 stacks (62.3%)
BPC-157 72 stacks (46.8%)
TB-500 55 stacks (35.7%)
Retatrutide 40 stacks (26%)
Tirzepatide 21 stacks (13.6%)

Switching Patterns

Based on 89 discussions about switching to or from KPV.

→ Switching FROM

GHK-Cu 19 mentions
Retatrutide 18 mentions
BPC-157 9 mentions
MOTS-c 6 mentions

Users who switched to KPV

← Switching TO

GHK-Cu 14 mentions
Retatrutide 12 mentions
BPC-157 4 mentions
MOTS-c 4 mentions

Users who switched from KPV